Discovery of way to match pathogens to their antibodies

The search for a vaccination against HIV has been in progress since 1984, with very little success.

Traditional methods used for identifying potential cellular targets can be very costly and time-consuming. The key to creating a vaccination lies in knowing which parts of the pathogen to target with which antibodies. A new study by David Heckerman and colleagues from Massachusetts General Hospital, publishing on October 12, 2007, in PLoS Computational Biology, has come up with a way to match pathogens to their antibodies.

At the core of the human immune response is the train-to-kill mechanism in which specialized immune cells are sensitized to recognize small peptides from foreign pathogens (e.g., HIV). Following this sensitization, these cells are then activated to kill cells that display this same peptide. However, for sensitization and killing to occur, the pathogen peptide must be “paired up” with one of the infected person's other specialized immune molecules—an HLA (human leukocyte antigen) molecule. The way in which pathogen peptides interact with these HLA molecules defines if and how an immune response will be generated.

Heckerman's model uses ELISpot assays to identify HLA-restricted epitopes, and which HLA alleles are responsible for which reactions towards which pathogens. The data generated about the immune response to pathogens fills in missing information from previous studies, and can be used to solve a variety of similar problems. The model was applied to data from donors with HIV, and made 12 correct predictions out of 16. This study, says David Heckerman, has “significant implications for the understanding of…vaccine development”. The statistical approach is unusual in the study of HLA molecules, and could lead the way to developing an HIV vaccine.

http://www.plos.org/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination